AstraZeneca (AZN) Stock Climbs on CEO Share Purchase and Klygefa EU Approval Recommendation

Key Highlights

• Pascal Soriot, AstraZeneca’s CEO, acquired 60,000 shares valued at £121.02 per share on September 14, 2026
• Europe’s CHMP committee delivered a favorable opinion supporting Klygefa (gefurulimab) approval for generalised myasthenia gravis
• The Phase III PREVAIL trial demonstrated Klygefa successfully achieved its primary endpoint, with findings featured in JAMA Neurology
• Upon approval, Klygefa stands to become the EU’s inaugural dual-binding nanobody C5 inhibitor for this rare disease population
• Applications for Klygefa authorization remain active across the US, China, and multiple international markets

In a notable display of executive confidence, Pascal Soriot, the chief executive of AstraZeneca, committed more than £7.26 million to acquire 60,000 ordinary shares of the company at £121.02 apiece through the London exchange on September 14, 2026. This transaction was formally reported in accordance with UK market abuse disclosure requirements.

AstraZeneca PLC, AZN

This significant share acquisition coincided with positive regulatory developments for Alexion, AstraZeneca’s specialized rare disease division, which secured important progress within European regulatory channels.

The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency delivered a favorable assessment supporting the authorization of Klygefa (gefurulimab) throughout the European Union. The proposed indication covers adjunctive treatment for generalised myasthenia gravis (gMG) in adult patients testing positive for anti-acetylcholine receptor (AChR) antibodies.

Generalised myasthenia gravis represents a rare autoimmune condition characterized by debilitating muscle weakness and compromised muscular performance. Data from five major European nations (Germany, France, the United Kingdom, Italy, and Spain) indicates approximately 82,500 individuals carry a gMG diagnosis, with roughly 66,000 classified as AChR-positive.

The foundation for the CHMP’s favorable opinion stemmed from data generated in the Phase III PREVAIL clinical trial. These study outcomes received publication in the peer-reviewed journal JAMA Neurology.

Within the trial framework, Klygefa successfully achieved its primary endpoint. Data revealed a statistically meaningful enhancement from baseline measurements in the Myasthenia Gravis Activities of Daily Living score at the 26-week mark when compared against placebo. The treatment differential registered at -1.6, accompanied by a p-value below 0.0001.

Clinical benefits emerged as soon as the first week of treatment and persisted consistently throughout the complete 26-week study duration.

Pioneering Treatment Option

Should the European Commission grant formal authorization following the CHMP guidance, which historically occurs in most cases, Klygefa would establish itself as the pioneering dual-binding nanobody C5 inhibitor sanctioned for this specific patient group within European markets.

The therapy requires once-weekly administration through subcutaneous self-injection utilizing an autoinjector device, offering patients a practical treatment solution suitable for home administration.

Clinical data characterized Klygefa as exhibiting favorable tolerability. The safety characteristics aligned closely with previous clinical experience involving C5 inhibitors eculizumab and ravulizumab in gMG patient populations.

Global Regulatory Status

Klygefa has secured marketing authorization in Japan and multiple additional territories for specific adult gMG patient populations.

Marketing applications founded on PREVAIL study data are presently undergoing regulatory assessment in the United States and China, alongside evaluations in other international jurisdictions.

AZN stock registered a 0.63% increase at the time of this report. Current analyst consensus on AZN maintains a Buy recommendation, establishing a price target of £15,200.

The company’s market capitalization currently stands at £188.2 billion, with typical daily trading activity averaging approximately 3.3 million shares.